End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study.
Jesper van BreeschotenRawa Kamaran IsmailMichel W J M WoutersDoranne L HilariusLiesbeth C de WreedeJohn B A G HaanenChristian U BlankMaureen J B AartsFranchette W P J van den BerkmortelJan Willem B de GrootGeke A P HospersEllen KapiteijnDjura PiersmaRozemarijn S van RijnMarion A Stevense-den BoerAstrid A M van der VeldtGerard VreugdenhilMarye J Boers-SonderenKarijn P M SuijkerbuijkAlfons J M van den EertweghPublished in: JCO oncology practice (2022)
The minority of Dutch patients with metastatic melanoma started a new systemic therapy in the last phase of life. However, the percentages varied between Dutch melanoma centers. Financial impact of these therapies in the last phase of life is relatively small.